Claims for Patent: 10,143,755

Summary for Patent: 10,143,755

Title:	Anhydrous hydrogel composition and delivery system
Abstract:	The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API\'s), coagulants, fragrances, flavors, and other actives and excipients.
Inventor(s):	Borja; John (Keyport, NJ), Hayano; Stephanie Sharon (Millerton, NY)
Assignee:	Acupac Packaging Inc. (Mahwah, NJ)
Application Number:	15/835,517
Patent Claims:	1. An active agent delivery system, comprising a. a solid or semi-solid gel composition including a reservoir, the solid or semi-solid gel composition comprising: i. sodium carboxymethyl cellulose (NaCMC) in an amount of from 5% (w/w) to 30% (w/w), said sodium carboxymethyl cellulose including minimal residual water, and ii. anhydrous glycerine in an amount of from 70% (w/w) to 95% (w/w); and b. the reservoir including an active agent. 2. The active agent delivery system of claim 1, wherein the active agent delivery system is a patch, capsule, lozenge or chew. 3. The active agent delivery system of claim 1, wherein the amount of active agent is from 0.1% (w/w) to 30% (w/w). 4. The active agent delivery system of claim 1, wherein the solid or semi-solid gel composition includes an interior and the reservoir is within the interior. 5. The active agent delivery system of claim 1, wherein said active agent is cannabidiol (CBD). 6. The active agent delivery system of claim 1, wherein said active agent is selected from cannabidiol (CBD) oil and tetrahydrocannabinol (THC) oil. 7. The active agent delivery system of claim 1, wherein said active agent is a moisture sensitive active agent and said moisture sensitive active agent comprises pharmaceutical agents including biologicals, enzymes, proteins and fragments thereof, Adderall, alprazolam, gemifloxacin, hydromorphone and zolmitriptan. 8. The active agent delivery system of claim 1, wherein said active agent is a pharmaceutical agent selected from analgesics, decongestants, bronchodilators, antiasthmatic agents, cardiovascular agents, diabetic agents, antihistamines, anesthetics, antifungals, anti-nauseants, antiemetics, antibacterial agents, antifungal agents, corticosteroids, neurological agents, anti-inflammatories, vaccines, biological agents, wound healing agents, anticonvulsants and vitamins. 9. The active agent delivery system of claim 1, wherein said active agent is a wound healing agent selected from becaplermin, antimicrobial agents, silver, povidone-iodine, polyhexamethylene biguanide, dialkylcarbamoylchloride, lactoferrin, and growth factors. 10. An active agent delivery system, comprising b. a substrate; c. a solid or semi-solid gel composition on the substrate, the solid or semi-solid gel composition including: i. sodium carboxymethyl cellulose (NaCMC) in an amount of from 5% (w/w) to 30% (w/w), said sodium carboxymethyl cellulose including minimal residual water, ii. anhydrous glycerine in an amount of from 70% (w/w) to 95% (w/w) and iii. an active agent. 11. The active agent delivery system of claim 10, wherein the solid or semi-solid gel composition includes an interior, a reservoir is within the interior and the reservoir includes the active agent. 12. The active agent delivery system of claim 10, wherein the substrate is a backing layer or a release liner that covers a surface of the active agent delivery system that upon removal of the substrate becomes an exposed surface of the active agent delivery system to be applied to a body surface of a patient in active agent-transmitting relationship thereto. 13. The active agent delivery system of claim 10, wherein the active agent delivery system is a patch. 14. The active agent delivery system of claim 10, further including a skin contact adhesive to affix the active agent delivery system to a patient's body. 15. The active agent delivery system of claim 10, wherein said active agent is cannabidiol (CBD). 16. The active agent delivery system of claim 10, wherein said active agent is selected from cannabidiol (CBD) oil and tetrahydrocannabinol (THC) oil. 17. The active agent delivery system of claim 10, wherein s said active agent is a moisture sensitive active agent and said aid moisture sensitive active agent comprises pharmaceutical agents including biologicals, enzymes, proteins and fragments thereof, Adderall, alprazolam, gemifloxacin, hydromorphone and zolmitriptan. 18. The active agent delivery system of claim 10, wherein said active agent is a pharmaceutical agent selected from analgesics, decongestants, bronchodilators, antiasthmatic agents, cardiovascular agents, diabetic agents, antihistamines, anesthetics, antifungals, anti-nauseants, antiemetics, antibacterial agents, antifungal agents, corticosteroids, neurological agents, anti-inflammatories, vaccines, biological agents, wound healing agents, anticonvulsants and vitamins. 19. The active agent delivery system of claim 10, wherein said active agent is a wound healing agent selected from becaplermin, antimicrobial agents, silver, povidone-iodine, polyhexamethylene biguanide, dialkylcarbamoylchloride, lactoferrin, and growth factors. 20. A method of using an active agent delivery system, the active agent delivery system comprising a. a substrate including a backing layer or a release liner that covers a surface of the active agent delivery system; b. a solid or semi-solid gel composition including a reservoir, the solid or semi-solid gel composition comprising: i. sodium carboxymethyl cellulose (NaCMC) in an amount of from 5% (w/w) to 30% (w/w), said sodium carboxymethyl cellulose including minimal residual water, and ii. anhydrous glycerine in an amount of from 70% (w/w) to 95% (w/w); and c. the reservoir including an active agent, the method comprising: 1) removing the substrate from the active agent delivery system where upon removal, the surface of the active agent delivery system becomes an exposed surface of the active agent delivery system; and 2) applying the exposed surface of the active agent delivery system to a body surface of a patient in active agent-transmitting relationship thereto.

Details for Patent 10,143,755

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	12/16/1997		2033-05-17